Latest & Greatest

Latest & Greatest

Recent developments in the field of hematology/oncology, including drug approvals, policy updates, and clinical trial results

Indication Expanded for Gemtuzumab Ozogamicin

The FDA has extended the indication of gemtuzumab ozogamicin to include pediatric patients aged 1 month or older with newly diagnosed CD33-positive acute myeloid...

Oral Selinexor Approved for Relapsed/Refractory DLBCL

The FDA has granted accelerated approval to selinexor for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including DLBCL...

White House Extends Work Visa Suspensions

The White House has announced the restriction of several categories of work visas for non-American citizens, in response to high unemployment levels following the...

FDA Releases Statistical Guidance for Clinical Trials Affected by COVID-19

The FDA has released new guidance regarding statistical considerations for clinical trials affected by the COVID-19 pandemic, with the aim of maintaining integrity of...

FDA Grants Accelerated Approval to Tazemetostat for Follicular Lymphoma

Tazemetostat, an enhancer of zeste homolog 2 (EZH2) gene inhibitor, was granted accelerated approval for two indications in adults with relapsed or refractory follicular...

CMS Proposes Higher Reimbursement Rate for CAR T-Cell Therapies

The Centers for Medicare and Medicaid Services (CMS) has proposed a new system for calculating reimbursement rates for hospitals administering chimeric antigen receptor (CAR)...

PTG-300 Receives Orphan Drug Designation for Treatment of Polycythemia Vera

The FDA granted orphan drug designation to PTG-300 for the treatment of phlebotomy-requiring polycythemia vera (PV). PTG-300 is an injectable synthetic hepcidin mimetic in...

FDA Partners With NY Health Tech Firm to Collect Real-world COVID-19 Data

The FDA announced a new research project to collect real-world data from insurance companies and electronic health records on the use of diagnostic tests...

Daratumumab and Hyaluronidase-fihj Approved For Patients With Myeloma

The FDA has approved a new subcutaneous formulation of daratumumab and hyaluronidase-fihj for adult patients with newly-diagnosed or relapsed/refractory multiple myeloma (MM). Daratumumab was...

FDA Grants Orphan Drug Designation to MT-401 for AML

The FDA has granted orphan drug designation to MT-401, an allogeneic T-cell therapy for the treatment of acute myeloid leukemia (AML). MT-401, from Marker Therapeutics,...
Advertisement

Current Issue

August 2020 Volume 6, Issue 10

This issue looks at the rapid expansion of telemedicine, explores access to leukemia treatment in Brazil, and more.

Block title